Dengue Vaccine – QDENGA (TAK-003)

Prelims: *Current events of national and international importance | Health*

Why in News?

Recently, the Drug Controller General of India (DCGI) has granted market authorisation to Takeda Biopharmaceuticals India's QDENGA (TAK-003), making it the first dengue vaccine approved in India.

- **Type – *Live-attenuated tetravalent vaccine***, protecting against all four dengue virus serotypes.
- **Dosage –** Two subcutaneous injections (0.5 ml each) are given three months apart.
- **Age Group –** Approved for individuals aged 4 to 60 years.
- **Screening –** Does not require pre-vaccination dengue screening, simplifying administration.
- **WHO Recommendation –** For dengue-endemic regions with high transmission.
- WHO prequalification enables procurement by UNICEF and PAHO.
- **Global Approvals –** Licensed in 43 countries across Asia, Latin America, and Europe.
- **Global Standing –** Aligns India with WHO-endorsed dengue control strategies.

Reference

The Hindu | Dengue Vaccine